Загрузка...
A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro
Background. The detoxified TLR4-ligand Monophosphoryl Lipid A (MPLA) is the first approved TLR-agonist used as adjuvant in licensed vaccines but has not yet been explored as part of conjugated vaccines. Objective. To investigate the immune-modulating properties of a fusion protein consisting of MPLA...
Сохранить в:
| Опубликовано в: : | J Immunol Res |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Hindawi Publishing Corporation
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4908266/ https://ncbi.nlm.nih.gov/pubmed/27340679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4156456 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|